Correction to: Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML

Cell Death Discov. 2021 Jul 6;7(1):171. doi: 10.1038/s41420-021-00558-1.

¹ Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
² Department of Pathology, Phramongkutklao College of Medicine, Bangkok, Thailand.
³ Cyclacel Limited, Dundee, UK.
⁴ Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. mhairi.copland@glasgow.ac.uk.

No abstract available

Publication types